SECURITIES AND EXCHANGE
COMMISSION WASHINGTON, DC
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of
1934
Date of Report: January 28, 1997
(Date of earliest event reported)
LIDAK PHARMACEUTICALS
(Exact name of registrant as specified in its charter)
CALIFORNIA
(State or other jurisdiction of incorporation)
0-18734 33-0314804
(Commission File Number) (IRS Employer
Identification No.)
11077 North Torrey Pines Road, La Jolla, California 92037
(Address of principal executive offices) (Zip code)
(619) 558-0364
(Registrants telephone number, including area code)
<PAGE>
Item 5. OTHER EVENTS
On January 28, 1997, the Company announced that it's
Board of Directors is extending the February 26, 1997
expiration date of its Class D Warrants to December 31, 1997.
The Class D Warrants, which were issued in connection
with a Private Financing completed in February 1992, entitles
holders to purchase one share of the Company's Class A Common
Stock for each warrant at an exercise price of $1.50.
SIGNATURES
Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned
hereunto duly authorized.
LIDAK PHARMACEUTICALS
Date: February 11, 1997 By:/s/David H. Katz
-----------------------------
President and Chief
Executive Officer
